dm+d

24002411000001100

Articles

Search Articles

Refrigerated Storage

KadcylaRoche Products Ltd

Roche Products Ltd
Kadcyla
100 mg and 160 mg Powder for concentrate for solution for infusion

Contact Roche Products Ltd in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.

28 September 2020
London MI Service

New Medicines

KadcylaMetastatic HER2-positive, PD-L1-positive breast cancer - second-line plus with atezolizumab

Information

Kadcyla
Licence extension / variation
Roche
Roche

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Antibody-drug conjugate, consists of DM1 cancer-cell killing agent linked to HER2-targeted antibody, trastuzumab
In 2012, the estimated age-adjusted annual incidence of breast cancer in 40 European countries was 94.2 per 100,000 and the mortality 23.1 per 100,000. About 15% of breast cancers have amplification of the HER2 gene and these cancers have an intrinsically worse prognosis than other cancers [1]. Breast cancer is highly heterogeneous, and PD-1/PD-L1 expression may vary among different molecular subtypes [2].
Metastatic HER2-positive, PD-L1-positive breast cancer - second-line plus with atezolizumab
Intravenous infusion